- Home
- FHTX vs NGEN Comparison
FHTX vs NGEN Comparison
Compare FHTX & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FHTX | NGEN |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | Canada |
| Employees | N/A | 9 |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.4M | 314.8M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | FHTX | NGEN |
|---|---|---|
| Price | $4.26 | $3.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | $11.50 | ★ $18.00 |
| AVG Volume (30 Days) | 106.1K | ★ 177.8K |
| Earning Date | 05-06-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.32 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,909,000.00 | N/A |
| Revenue This Year | $8.89 | N/A |
| Revenue Next Year | $20.13 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 36.75 | N/A |
| 52 Week Low | $3.27 | $3.51 |
| 52 Week High | $6.95 | $5.93 |
Technical Indicators
Market Signals| Indicator | FHTX | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 32.46 | 49.01 |
| Support Level | $3.65 | $3.65 |
| Resistance Level | $5.82 | $4.44 |
| Average True Range (ATR) | 0.29 | 0.20 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 10.00 | 58.34 |
Price Performance
Historical ComparisonAbout FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.